Catalyst Pharmaceuticals is planning to request that the approved use of Firdapse in the U.S. be expanded to include children…
Articles by Marisa Wexler, MS
Investment in companies developing treatments for Lambert-Eaton myasthenic syndrome (LEMS) and other rare diseases increased by 28% in 2021…
A federal appeals court has denied Jacobus Pharmaceutical’s petition to rehear its prior ruling overturning the U.S. approval of the…
A federal appeals court has ruled that the U.S. Food and Drug Administration (FDA) should not have approved Ruzurgi…
Cholinesterase inhibitors may be useful in controlling the symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in people with relatively…
Jacobus Pharmaceutical has issued a voluntary recall for three lots of Ruzurgi (amifampridine), a medication that is approved in…
Immunofluorescence, a technique that can be used to detect antibodies associated with Lambert-Eaton myasthenic syndrome (LEMS), was negative in…
A woman with Lambert-Eaton myasthenic syndrome (LEMS) twice tested positive for a rare but high-risk blood marker of cancer,…
Catalyst Pharmaceuticals has secured a second U.S. patent covering Firdapse (amifampridine), an approved oral treatment for Lambert-Eaton myasthenic…
Catalyst Pharmaceuticals has teamed up with DyDo Pharma to develop and commercialize Firdapse (amifampridine) in Japan for the treatment…